Drugs / Recombinant human interferon-gamma
Recombinant human interferon-gamma
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04990232 | Jul 2021 → Feb 2024 | infectious disease with sepsis | Hellenic Institute for the Study of Sepsis | Completed | Met primary |
| Phase 2 | NCT03332225 | Dec 2017 → Dec 2019 | infectious disease with sepsis, macrophage activation syndrome | Hellenic Institute for the Study of Sepsis | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human interferon-gamma | “In the active immunotherapy arm, patients with MALS will receive anakinra (recombinant interleukin-1 receptor antagonist) intravenously, and patients with immunoparalysis will...” PMID 36600424 ↗ Dec 2022 |
| Known as | IFNγ | “The best candidate drug for this would be interferon gamma (IFNγ).” NCT03332225 ↗ |
| Known as | rhIFNγ | “IV anakinra 200 mg three times daily (every eight hours) or sc rhIFNγ 100 μg once every other day.” NCT04990232 ↗1“recombinant human interferon-gamma (rhIFNγ)” NCT03332225 ↗ |
| Action | Restore | “Immunosuppression established in healthy volunteers after experimental endotoxemia was reversed after administration of recombinant human interferon-gamma (rhIFNγ).” NCT03332225 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human interferon-gamma (rhIFNγ)” NCT03332225 ↗ |
| Route | Subcutaneous | “Treatment with sc recombinant human interferon-gamma every other day for a total of 15 days” NCT03332225 ↗ |